City Therapeutics Inc.
CTY | NASDAQ
$20.71
-$1.43 (-6.46%)
At close: Oct 30, 2026, 4:00 PM ET
Market Data
Market Cap $201.35M
Enterprise Value $4.86B
Beta 0.00
Average Volume 372.03K
Shares Outstanding (Diluted) N/A
Shares Change YoY N/A
Institutional Ownership N/A
Exchange NASDAQ
ISIN US1787821081
Price Performance
Price Change 1M -17.3%
Price Change 3M -17.3%
Price Change 6M -17.3%
Price Change YTD -17.3%
Price Change 1Y -17.3%
Price Change 3Y -17.3%
Price Change 5Y -17.3%
1M CAGR (ann.) -19.3%
1Y CAGR (ann.) -16.5%
5Y CAGR (ann.) N/A
All-Time CAGR -2.0%
Valuation
PE Ratio N/A
Forward PE N/A
PEG Ratio 0.00
Forward PEG 0.00
PS Ratio 0.03
Forward PS N/A
PB Ratio 0.02
P/FCF Ratio 0.09
P/Adj. FCF Ratio 0.09
P/OCF Ratio N/A
EV/Sales 0.75
EV/EBIT 4.98
EV/EBITDA 1.36
EV/FCF 2.24
Earnings Yield 0.0%
FCF Yield 1076.3%
Adj. FCF Yield 1063.3%
Financial Health
Net Debt $4.66B
Total Debt $4.66B
Cash & Short-Term Investments $5M
Total Assets $19.45B
Current Ratio 0.73
Quick Ratio 0.73
Debt / Equity Ratio 0.59
Debt / EBITDA 1.30
Debt / FCF 2.15
OCF / Debt 0.71
Interest Coverage 0.00
Altman Z-Score 0.46
Piotroski F-Score 6
Margins & Profitability
Gross Profit Margin 70.1%
Operating Profit Margin 43.6%
EBITDA Margin 47.0%
Net Profit Margin 22.4%
FCF Margin 33.4%
Adj. FCF Margin 33.0%
SBC / Revenue 0.3%
SBC Impact (per share) -1.2%
Returns
Return on Assets 8.7%
Return on Equity 18.3%
Return on Invested Capital 11.4%
Return on Capital Employed 16.4%
Return on Tangible Assets 16.4%
Historical Growth (CAGR)
Revenue CAGR 3Y -9.4%
Revenue CAGR 5Y -6.0%
Revenue CAGR 10Y -3.6%
EPS CAGR 3Y N/A
EPS CAGR 5Y N/A
EPS CAGR 10Y N/A
FCF CAGR 3Y 22.5%
FCF CAGR 5Y 6.9%
FCF CAGR 10Y 2.2%
Analyst Forecasts
Analyst Rating Hold
Analyst Count 0
EPS Growth Next 3Y N/A
Revenue Growth Next 3Y N/A
Earnings Date N/A
EPS Estimate (next Q) N/A
EPS Growth Est (next Q) N/A
Revenue Est (next Q) N/A
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $0.00
Price Target Upside N/A
Cash Flow
Operating Cash Flow $3.31B
Free Cash Flow $2.17B
Adj. Free Cash Flow $2.14B
FCF Per Share $0.00
OCF Per Share $0.00
OCF/S Ratio 40.8%
Income Statement
Revenue $6.49B
Gross Profit $4.29B
Operating Income $2.83B
EBITDA $3.58B
Net Income $1.8B
EPS (Diluted) $0.00
Revenue / Employee $86.57M
Profit / Employee $23.95M
Employees 75
Add to Watchlist
Select watchlists to add or remove CTY